The optimum management of uveal melanoma is uncertain. A number of retrospective studies have shown no evidence that the type of ocular therapy, either locally effective radiation or enucleation, has a definitive survival advantage.1-6 In September 1985 the Collaborative Ocular Melanoma Study (COMS) was initiated to evaluate the effect of brachytherapy versus enucleation on survival in some patients with uveal melanoma. 7 The incidence of metastatic deaths in patients eligible for entry into that trial, who were treated more than 5 years ago and had 100% follow up after helium ion radiation, was approximately 10%.8 The absence of a demonstrable survival advantage with enucleation and doubts about the potential of a study with a low metastatic death rate to demonstrate a significant treatment effect led many American ocular oncologists not to participate in the above trial.9
Obvious advantages of retaining an eye include cosmesis and function. In both prospective and retrospective analyses of irradiated uveal melanoma patients, factors shown to correlate with visual outcome include tumour thickness, tumour location, pretreatment visual acuity, age, and type of radiation. 4 8 10-12 As an example, 5 years after helium ion radiation approximately 60% of patients with tumours <6 mm thick that were >3 mm from the nerve or fovea had >6/15 vision.8 In contrast, less than one quarter of patients with either thicker tumours, those melanomas <3 mm from the nerve or fovea, or both, retained that level of vision. In this study, we reviewed retrospectively uveal melanoma patients we irradiated who would have been eligible for entry into the COMS trial of enucleation versus brachytherapy to determine their long term visual outcomes and to assess the relative importance of tumour and patient factors on post-radiation visual retention. We also compared metastatic rates of individuals as a function of their pretreatment risk of visual loss.
Materials and methods
We reviewed retrospectively the records of the 718 patients with irradiated uveal melanoma treated between 1978 and 1993. We selected all cases that met the entrance criteria for the COMS trial comparing enucleation with radiation.7 Briefly, the major ocular entrance criteria involved tumour size and tumour location. Uveal melanomas had to be no greater than 16 mm in diameter and between 2-5 to 8 mm in height. More recently, the size criterion has been modified to include patients with tumours up to 10 mm in height. Location restrictions were that tumours could not be contiguous to the optic disc. If they were within 2 mm of the disc and involved less than 3 clock hours, they could be entered at the discretion of the surgeon. Tumours were excluded if the majority of the tumour involved the ciliary body or if the iris-corneal angle was involved. When these criteria were applied to our database, 221 tumours were excluded because of tumour size and/or tumour location criteria (Table 1 ). An additional 29 tumours were excluded because of previous therapy, and six were excluded because they lacked adequate post-treatment visual acuity data.
The emphasis of our investigation was visual outcome, so we analysed our data with and without some patients who did not meet the non-ocular COMS criteria. The majority of these latter exclusion criteria involved either The mean length of time for treatment to last visual assessment was 5 years (median 4 1 (range 0-1 to 16-3) years). Limited follow up because of either enucleation or death was 31 2%; 52 cases were enucleated. The mean length of time from treatment to last patient contact was 6 1 years (median 5-6 (range 02 to 16-4) years).
Generally, patients were examined by us with clinical evaluation, ultrasonography and eye photography before and 3 months after treatment. Most patients were evaluated every 4 months during the first post-treatment year, 6 months the second year, 9 months the third year, then yearly after treatment. Some patients, primarily because of travel restrictions, were followed by local ophthalmologists. A total of 3015 post-treatment visual follow up measures were used for this study of which 76% were performed at UCSF. Mortality and metastatic information was obtained from family members, death certificates, tumour registries, and/or primary physicians. In the 52 cases enucleated after radiation, the visual acuities for these cases were classified as no light perception at the time of enucleation.
STATISTICAL METHODS
Statistical analyses were performed using semiparametric and non-parametric methods including Kaplan- Seventeen patients who presented with visual acuity worse than 6/120 were excluded from these analyses. To model the retention of visual acuity, the time to visual acuity worse than 6/12 was selected. Noting that visual acuity improvement after irradiation was rare, the analyses were restricted to the 302 patients with visual acuity of 6/12 or better at the time of treatment. A third analysis to examine the length of useful visual function was also performed. For this analysis the time to visual acuity of 6/120 or worse was selected for the 400 patients with pretreatment visual acuity better than 6/120. Problems as a result of transitory visual loss, interval censoring, dependent censoring, and loss of information by ignoring the actual visual acuity at the endpoint arose in all models.
Transitory visual loss was present in 16-23% of the cases depending on the model's visual threshold. The majority occurred within the first year after treatment reflecting a Interval censoring reflects that a patient had not reached an endpoint at one follow up but reached the endpoint by the time of the next follow up. In 80% of the patients the time between the last follow up before visual loss and the follow up with visual loss was under 1 year. Other analyses using the follow up before the visual loss or the interpolated date of visual loss suggested that ignoring the interval censoring did not dramatically affect the covariate conclusions as has been noted in other studies.'9 The time to visual loss was slightly underestimated when visual loss occurred before the time of visual assessment.
Another problem in longitudinal data analysis occurs with dependent censoring when either cases censored by death were at higher risk of visual loss or when poor visual outcome cases are censored by follow up refusal before an endpoint was reached.20 For two analyses we used a low threshold for visual loss so that only 34% of cases were censored with less than 6% of the cases censored owing to death and the others censored owing to the time of analysis. The limited censoring and the majority of censoring, which were the result of the time of our study, suggested that the uninformative censoring assumption was reasonable in these analyses. The analysis for the time until visual acuity of -6/120 led to greater censoring owing to death. As ciliary body involvement, larger tumour size, and older age were each predictors of visual loss and predictors of tumour or non-tumour related mortality, some dependent censoring was present.
Results
Patients who were followed for 3 years with eye retention or enucleated within 3 years were subgrouped into three visual outcome categories. Good visual outcome was defined as best corrected visual acuity of 6/12 or better at any follow up at least 3 years after treatment. Poor visual outcome was defined as best corrected visual acuity of 6/120 or worse at all follow ups after 3 years. The middle subgroup consisted of the remaining patients. The visual acuity at the time of treatment was predictive of the visual outcome (Table 3) . While 42-0% of patients with preoperative visual acuity of 6/12 or better led to good visual outcomes of 6/12 or better after 3 years, only six of 62 patients with preoperative visual acuities between 6/15 and 6/60, and none of the 16 patients with preoperative visual acuities worse than 6/60, had good visual outcomes. The majority of patients with poorer visual acuity at treatment had poor visual outcomes. The model was also fit within each treatment arm. There was a tendency for a more pronounced detrimental effect of tumour thickness on visual outcome in the iodine-125 plaque cases and a more pronounced effect of both posterior and anterior location in the helium ion cases. Minimum treatment dose was not contributory in any of the models suggesting that the doses given are above a visual retention threshold.
Kaplan-Meier time to onset curves for the two predominant visual acuity predictors (size and location) are given in Figure 1 . Each group was stratified so that roughly half of the cases were in each stratum. The effect of both tumour size and tumour location was dramatic. Kaplan-Meier curves are also given for the stratified relative risk (RR) for three strata. While the 5 year rate of visual loss was 87 6% for the lower stratum, it was 410% for the higher stratum. The rate of visual loss was analysed using cumulative hazard plots for the time to loss of three, six, and nine lines (Fig 2) . These line losses are equivalent to a doubling, quadrupling, and octupling of the minimal angle of resolution. The plots were restricted to patients with preoperative visual acuities of :6/60. The slopes of the cumulative hazard indicate the rate of visual loss. The visual loss rate is greatest immediately after treatment and decreases further about 4 years after treatment.
We assessed the rate of visual loss for patients who had maintained -6/12 visual acuity for 3 years after treatment. Seventy three (35 helium ion patients and 38 iodine-125 plaque patients) of the 101 patients who had maintained 6/12 or better visual acuity at a follow up after 3 years had additional follow up. Of these 73 patients, 63 patients retained visual acuities of 6/24 or better at their last visual examination (Fig 3) . The reasons for the late onset visual loss in this cohort were late onset radiation retinopathy (five), enucleation (two), vitreous haemorrhage (two), and radiation cataract (one). The mean post-treatment follow up length of this cohort was 7 0 years. These results suggest that if good visual acuity is maintained for 3 to 4 years after treatment, there is a higher probability that it will be maintained for a longer time.
A visual acuity of <6/12 was selected to define the retention of good vision. A total of 119 of the 302 patients with pre-treatment acuity -6/12 had not reached this visual endpoint as of last follow up. Cox model results are given in Table 5 and are similar to those for time to visual loss. The predominant predictors of visual retention were tumour thickness, tumour location (with respect to the nerve, fovea, and ciliary body), patient age, and the degree of subretinal detachment. Again there was a tendency for a more pronounced effect of tumour thickness in the iodine-125 plaque cases and a more pronounced effect of tumour location with respect to the nerve and fovea or ciliary body in helium ion cases. Kaplan-Meier curves for the time to onset stratified by size, location, and relative risk are given in Figure 4 . The 3 and 5 year rates of visual retention of patients with preoperative visual acuity of ¢6/12 were 48 2% and 36-1% respectively.
An endpoint of 6/120 or worse was selected to define the loss of visual function. A total of 192 of the 400 patients with pre-treatment acuity :6/60 Time (years) Figure 1 (A) Kaplan-Meier survival estimates for time until e3 line loss for 409 patients with pre-treatment visual acuity (VA) of -6/120 stratified by (A) pre-treatment ultrasound tumour height; (B) pre-treatment tumour location with respect to the nerve, fovea, and ciliary body; (C) Cox model estimated relative risk.
was in models of visual retention. There was a tendency for a more pronounced effect of tumour thickness in the iodine-i 25 plaque cases and a more pronounced effect of tumour location with respect to the nerve and fovea or ciliary body in helium ion cases. Kaplan-Meier curves to time to onset for stratified cases are given in Figure 5 .
To examine possible correlations between the visual prognostic indicators and tumour related mortality, we stratified our patient cohort of 426 individuals into three categories. (Table 7) .
Overall 54 of the 426 patients have developed detectable melanoma metastases. Kaplan-Meier survival curves are given for each of the three strata in Figure 6 *Cox model relative risk per unit scale change. tNinety five per cent confidence interval for relative risk. tZ statistic, absolute values of statistic greater than 1-7, 2-3, and 3-1 (2-0, 2-6, and 3-3) are equivalent to one sided (two sided) p values of less than 0-05, 0-01, and 0-001 respectively. §Likelihood ratio statistic, asymptotically x2 distributed (degrees of freedom).
42% of cases.
Other studies have demonstrated previously that treatment of tumours contiguous or involving the fovea or optic nerve have relatively poorer visual outcome.8 12 21 In several multivariate analyses, tumour thickness, initial acuity, patient age, and type of radiation, in addition to tumour location, are important factors in visual outcome.8 10 11
Good visual acuity at 3 years after radiation was an excellent predictor of longer term visual prognosis. In those patients with >6/12 acuities at over 3 years, 63/73 (86%) were :6/24 with a mean post-treatment follow up of 7 0 years. Undoubtedly, in older patients acuity will diminish further over time; however, as previously described with charged particles, the time frame chosen is such that it is unlikely that many of these eyes will be lost from neovascular glaucoma, although visually significant cataract continues to develop in approximately 8% per year of follow up.22 This study demonstrates that long term visual outcome can be predicted based on the preoperative visual acuity, the tumour location with respect to the optic nerve and fovea and ciliary body, the tumour thickness, and the patient age. For example, 57 of the 74 (77%) patients with choroidal tumours thinner than 4*5 mm and located at least 3 mm from the nerve and fovea had kept their preoperative visual acuity of 6/12 or better at a mean follow up of 6-5 years. This percentage was higher in the younger patients. The lower metastatic rate within this group will contribute less information (for example, number of metastatic cases) Time (years) 8 10 Time ( risk of metastatic onset. There were two contributing factors. The poor vision group was most dependent on tumour height, and these thicker tumours have larger diameters, a known prognostic indicator for metastatic risk.
The poor vision group also contained 26 of the 44 tumours involving the ciliary body, another known metastatic risk indicator. Both the good and medium visual prognostic groups had 5 year metastatic estimates under 10%. No significant treatment differences between helium ion irradiation and 125I
brachytherapy visual outcomes were found after Cox model covariate adjustments. Some Table 6 Cox proportional hazards summaty for time until -6/120for the 400 patients with pre-treatment visual acuity of >6/120 We have delineated a subgroup with high probability of visual retention. In this patient group it appears to us that retention of the eye is useful and can often be accomplished with Time (years) Figure 5 Kaplan-Meier survival estimates for time until -6/120for 400 patients with pre-treatment visual acuity of >6/120 stratified by (A) pre-treatment ultrasound tumour height; (B) pre-treatment tumour location with respect to the nerve, fovea and ciliary body; (C) Cox 
